TORONTO, ONTARIO--(Marketwire - July 29, 2008) - Lorus Therapeutics Inc. (TSX: LOR)(AMEX: LRP) (“Lorus”), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced the allowance of a new patent from the United States Patent and Trademark Office for its clinical-stage anticancer drug LOR-2040.
